Loading...
Loading...
Browse all stories on DeepNewz
VisitFirst Major Pharmaceutical Company to Partner on eePASSIGE?
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Roche • 25%
Press releases and official announcements from pharmaceutical companies and research institutions
New eePASSIGE System Enhances Gene Editing in Human Cells at Therapeutic Levels
Jun 10, 2024, 02:11 PM
A new gene-editing system called eePASSIGE, which combines evolved and engineered recombinases with prime editing, has been reported in Nature Biomedical Engineering. This system enables the efficient, precise, and targeted integration of large gene-sized DNA cargoes into the mammalian genome. The approach aims to insert or substitute gene-sized DNA segments in human cells at therapeutic levels, potentially paving the way for one-size-fits-all gene therapies for diseases such as cystic fibrosis. Researchers are discussing the distinctions between these approaches and their potential applications in genomic medicine.
View original story
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Another Company • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
Yes • 50%
No • 50%
No collaboration • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
No • 50%
Yes • 50%
Nobel Prize • 33%
Breakthrough Prize • 33%
Lasker Award • 33%